15 patents
Utility
Methods And Compositions For Cancer Therapies That Include Delivery Of Halogenated Thymidines And Thymidine Phosphorylase Inhibitors In Combination With Radiation
28 Sep 23
Methods and formulations are provided for treating cancer and neoplastic diseases in conjunction with radiation therapy where such methods and formulations include a combination of a radiosensitizing agent that is metabolized by thymidine phosphorylase and a thymidine phosphorylase inhibitor that increases the half-life of the radiosensitizing agent.
Scott Grindrod, Mira Jung, Olga Timofeeva, Milton Brown, Anatoly Dritschilo
Filed: 2 Apr 23
Utility
Methods and compositions for cancer therapies that include delivery of halogenated thymidines and thymidine phosphorylase inhibitors in combination with radiation
23 May 23
Methods and formulations are provided for treating cancer and neoplastic diseases in conjunction with radiation therapy where such methods and formulations include a combination of a radiosensitizing agent that is metabolized by thymidine phosphorylase and a thymidine phosphorylase inhibitor that increases the half-life of the radiosensitizing agent.
Scott Grindrod, Mira Jung, Olga Timofeeva, Milton Brown, Anatoly Dritschilo
Filed: 9 Jan 18
Utility
Selective histone deacetylase inhibitors for the treatment of human disease
21 Feb 23
Selective HDAC inhibitors, and pharmaceutical compositions that include the same, are described herein for the treatment of cancer, immunological diseases, inflammatory diseases, and neurological diseases.
Scott Grindrod, Mira Jung, Milton Brown, Anatoly Dritschilo
Filed: 10 May 21
Utility
Selective Histone Deacetylase Inhibitors for the Treatment of Human Disease
17 Nov 22
Selective HDAC inhibitors, and pharmaceutical compositions that include the same, are described herein for the treatment of cancer, immunological diseases, inflammatory diseases, and neurological diseases.
Scott Grindrod, Mira Jung, Anatoly Dritschilo
Filed: 28 Jun 22
Utility
CorrectedSelective Histone Deacetylase Inhibitors for the Treatment of Human Disease
3 Nov 22
Selective HDAC inhibitors, and pharmaceutical compositions that include the same, are described herein for the treatment of cancer, immunological diseases, inflammatory diseases, and neurological diseases.
Scott Grindrod, Mira Jung, Milton Brown, Anatoly Dritschilo
Filed: 10 May 21
Utility
Selective histone deacetylase inhibitors for the treatment of human disease
9 Aug 22
Selective HDAC inhibitors, and pharmaceutical compositions that include the same, are described herein for the treatment of cancer, immunological diseases, inflammatory diseases, and neurological diseases.
Scott Grindrod, Mira Jung, Anatoly Dritschilo
Filed: 8 Jan 19
Utility
Dual Function Molecules for Histone Deacetylase Inhibition and Ataxia Telangiectasia Mutated Activation and Methods of Use Thereof
24 Feb 22
Dual function compounds are provided that may be inhibitors of histone deacetylase (HDAC) and activators of ataxia telangiectasia mutated (ATM).
Scott GRINDROD, Mira JUNG, Milton BROWN, Anatoly DRITSCHILO
Filed: 24 Sep 21
Utility
Selective Histone Deacetylase Inhibitors for the Treatment of Human Disease
26 Aug 21
Selective HDAC inhibitors, and pharmaceutical compositions that include the same, are described herein for the treatment of cancer, immunological diseases, inflammatory diseases, and neurological diseases.
Scott Grindrod, Mira Jung, Milton Brown, Anatoly Dritschilo
Filed: 10 May 21
Utility
Selective histone deacetylase inhibitors for the treatment of human disease
15 Jun 21
Selective HDAC inhibitors, and pharmaceutical compositions that include the same, are described herein for the treatment of cancer, immunological diseases, inflammatory diseases, and neurological diseases.
Scott Grindrod, Mira Jung, Milton Brown, Anatoly Dritschilo
Filed: 9 Jan 18
Utility
Selective Histone Deacetylase Inhibitors for the Treatment of Human Disease
18 Mar 21
Selective HDAC inhibitors, and pharmaceutical compositions that include the same, are described herein for the treatment of cancer, immunological diseases, inflammatory diseases, and neurological diseases.
Scott Grindrod, Mira Jung, Anatoly Dritschilo
Filed: 8 Jan 19
Utility
Dual Function Molecules for Histone Deacetylase Inhibition and Ataxia Telangiectasia Mutated Activation and Methods of Use Thereof
7 Oct 20
Dual function compounds are provided that may be inhibitors of histone deacetylase (HDAC) and activators of ataxia telangiectasia mutated (ATM).
Scott GRINDROD, Mira JUNG, Milton BROWN, Anatoly DRITSCHILO
Filed: 23 Jun 20
Utility
Dual function molecules for histone deacetylase inhibition and ataxia telangiectasia mutated activation and methods of use thereof
17 Aug 20
Dual function compounds are provided that may be inhibitors of histone deacetylase (HDAC) and activators of ataxia telangiectasia mutated (ATM).
Scott Grindrod, Mira Jung, Milton Brown, Anatoly Dritschilo
Filed: 2 Mar 16
Utility
Dual function molecules for histone deacetylase inhibition and ataxia telangiectasia mutated activation and methods of use thereof
3 Aug 20
Dual function compounds are provided that may be inhibitors of histone deacetylase (HDAC) and activators of ataxia telangiectasia mutated (ATM).
Scott Grindrod, Mira Jung, Milton Brown, Anatoly Dritschilo
Filed: 5 Nov 17
Utility
Selective Histone Deacetylase Inhibitors for the Treatment of Human Disease
4 Mar 20
Selective HDAC inhibitors, and pharmaceutical compositions that include the same, are described herein for the treatment of cancer, immunological diseases, inflammatory diseases, and neurological diseases.
Scott Grindrod, Mira Jung, Milton Brown, Anatoly Dritschilo
Filed: 8 Jan 18
Utility
Methods And Compositions For Cancer Therapies That Include Delivery Of Halogenated Thymidines And Thymidine Phosphorylase Inhibitors In Combination With Radiation
13 Nov 19
Methods and formulations are provided for treating cancer and neoplastic diseases in conjunction with radiation therapy where such methods and formulations include a combination of a radiosensitizing agent that is metabolized by thymidine phosphorylase and a thymidine phosphorylase inhibitor that increases the half-life of the radiosensitizing agent.
Scott Grindrod, Mira Jung, Olga Timofeeva, Milton Brown, Anatoly Dritschilo
Filed: 8 Jan 18
- Prev
- 1
- Next
Patents are sorted by USPTO publication date, most recent first